Patents by Inventor Ying-Duo Gao

Ying-Duo Gao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR XIA INHIBITORS
    Publication number: 20240101567
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 28, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John S. Debenham, Cheng Zhu, Amjad Ali, Sung-Sau So, Ying-Duo Gao
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240025917
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jianming Bao, Natalija Cernaka, Alan C. Cheng, Ying-Duo Gao, Salman Jabri, Jovan Alexander Lopez, Rohan Merchant, Anthony Ken Ogawa, Skylar K. Osler, Christopher J. Sinz, Phillip Patrick Sharp, Haiqun Tang, Maoqun Tian, Dong Xiao, Song Yang
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230286958
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 14, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Salman Jabri, Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Brandon M. Taoka, Maoqun Tian, Galen Paul Shearn-Nance, Rongze Kuang, Matthew J. Lombardo, Zhicai Wu, Zhiqiang Zhao
  • FACTOR XI ACTIVATION INHIBITORS
    Publication number: 20230167085
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 1, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. HICKS, John S. Debenham, Amjad Ali, Ying-Duo Gao, Lan Wei, Dexi Yang, Rongze Kuang, Alan Hruza, Peter Nizner, Daniel A. Tatosian
  • FACTOR XI ACTIVATION INHIBITORS
    Publication number: 20230147170
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 11, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. Hicks, Amjad Ali, John S. Debenham, Anthony Donofrio, Wenlang Fu, Ying-Duo Gao, Alan Hruza, Yeon-Hee Lim, Matthew J. Lombardo, Peter Nizner, Sung-Sau So, Zheng Tan, Daniel A. Tatosian, Dong Xiao, Dexi Yang, Yang Yu
  • Factor XIA inhibitors
    Patent number: 10214512
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
  • FACTOR XIA INHIBITORS
    Publication number: 20180339977
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.
    Type: Application
    Filed: October 24, 2016
    Publication date: November 29, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
  • Factor XIa inhibitors
    Patent number: 10123995
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: November 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
  • Factor XIa inhibitors
    Patent number: 10093683
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: October 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yeon-Hee Lim, Zhuyan Guo, Amjad Ali, Scott D. Edmondson, Weiguo Liu, Gioconda V. Gallo-Etienne, Heping Wu, Ying-Duo Gao, Andrew W. Stamford, Younong Yu, Nancy J. Kevin, Rajan Anand, Deyou Sha, Santhosh F. Neelamkavil, Zahid Hussain, Puneet Kumar, Remond Moningka, Joseph L. Duffy, Jiayi Xu, Yu Jiang, Anjan Chakrabarti, Hiroki Sone
  • Factor XIa inhibitors
    Patent number: 10081617
    Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: September 25, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting
  • Factor XIa inhibitors
    Patent number: 10011585
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D Edmondson, Zhuyan Guo, Alan Hruza, Sung-Sau So, Wanying Sun, Amjad Ali, Rongze Kuang, Ying-Duo Gao, Anthony K Ogawa
  • Factor XIa inhibitors
    Patent number: 9975874
    Abstract: The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: May 22, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Scott D. Edmondson, Alan Hruza, Jiafang He, Sung-Sau So, Amjad Ali, Ying-Duo Gao
  • FACTOR XIa INHIBITORS
    Publication number: 20180079743
    Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting
  • Factor XIa inhibitors
    Patent number: 9868727
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 16, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Sung-Sau So, Anthony K. Ogawa, Rongze Kuang, Heping Wu, Amjad Ali, Ying-Duo Gao, Yu Jiang, Chunsing Li, Tingting Yu
  • FACTOR XIa INHIBITORS
    Publication number: 20180000795
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: January 15, 2016
    Publication date: January 4, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
  • Factor XIa Inhibitors
    Publication number: 20170240524
    Abstract: The present invention provides a compound of Formula (I) (Formula(I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: July 23, 2015
    Publication date: August 24, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Scott D. Edmondson, Alan Hruza, Jiafang He, Sung-Sau So, Amjad Ali, Ying-Duo Gao
  • FACTOR XIa INHIBITORS
    Publication number: 20170240523
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: July 23, 2015
    Publication date: August 24, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D Edmondson, Zhuyan Guo, Alan Hruza, Sung-Sau So, Wanying Sun, Amjad All, Rongze Kuang, Ying-Duo Gao, Anthony K Ogawa
  • Factor XIa Inhibitors
    Publication number: 20170210732
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: July 23, 2015
    Publication date: July 27, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Sung-Sau So, Anthony K. Ogawa, Rongze Kuang, Heping Wu, Amjad Ali, Ying-Duo Gao, Yu Jiang, Chunsing Li, Tingting Yu
  • FACTOR XIa INHIBITORS
    Publication number: 20170044183
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 16, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yeon-Hee Lim, Zhuyan Guo, Amjad Ali, Scott D. Edmondson, Weiguo Liu, Giocanda V. Gallo-Etienne, Heping Wu, Ying-Duo Gao, Andrew W. Stamford, Younong Yu, Nancy J. Kevin, Rajan Anand, Deyou Sha, Santhosh F. Neelamkavil, Zahid Hussain, Puneet Kumar, Remond Moningka, Joseph L. Duffy, Jiayi Xu, Yu Jiang, Anjan Chakrabarti, Hiroki Sone
  • Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
    Patent number: 9481682
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: November 1, 2016
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Ronald M. Kim, Jian Liu, Xiaolei Gao, Sobhana Babu Boga, Deodialsingh Guiadeen, Joseph A. Kozlowski, Wensheng Yu, Rajan Anand, Younong Yu, Oleg B. Selyutin, Ying-Duo Gao, Hao Wu, Shilan Liu, Chundao Yang, Hongjian Wang